CN109535249B - Monoclonal antibody ZKns3G2 and application thereof - Google Patents

Monoclonal antibody ZKns3G2 and application thereof Download PDF

Info

Publication number
CN109535249B
CN109535249B CN201811519058.1A CN201811519058A CN109535249B CN 109535249 B CN109535249 B CN 109535249B CN 201811519058 A CN201811519058 A CN 201811519058A CN 109535249 B CN109535249 B CN 109535249B
Authority
CN
China
Prior art keywords
antibody
monoclonal antibody
zkns3g2
variable region
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811519058.1A
Other languages
Chinese (zh)
Other versions
CN109535249A (en
Inventor
庾蕾
尹炽标
张复春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou 8th People's Hospital
Original Assignee
Guangzhou 8th People's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou 8th People's Hospital filed Critical Guangzhou 8th People's Hospital
Priority to CN201811519058.1A priority Critical patent/CN109535249B/en
Publication of CN109535249A publication Critical patent/CN109535249A/en
Application granted granted Critical
Publication of CN109535249B publication Critical patent/CN109535249B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention belongs to the technical field of biology, and particularly relates to a monoclonal antibody ZKns3G2 and application thereof. The monoclonal antibody ZKns3G2 provided by the invention is a fully human monoclonal antibody aiming at the Zika virus NS1 protein, and comprises a heavy chain variable region with an amino acid sequence shown in SEQ ID NO.1 and a light chain variable region with an amino acid sequence shown in SEQ ID NO. 2. The heavy chain and the light chain in the monoclonal antibody ZKns3G2 provided by the invention are naturally paired, so that the affinity of the antibody is high. Specifically binds to Zika virus NS1 protein, does not cross dengue virus NS1, and can be used as a diagnostic or therapeutic antibody.

Description

Monoclonal antibody ZKns3G2 and application thereof
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a monoclonal antibody ZKns3G2 and application thereof.
Background
ZIKV (ZIKV) is rapidly transmitted worldwide, especially in america, from 2015 to 2016, and has been declared by the WHO as an international public health emergency because it can cause serious birth defects and adult neurological complications.
ZIKV is also transmitted by aedes mosquitoes, often occurring in the dengue virus (DENV) endemic area. ZIKV and DENV are often present in the same region, but are different in clinical characteristics, hazards, and disposal. There is an urgent need to distinguish between these two viral infections as early as possible, especially for pregnant women. ZIKV and DENV belong to the same genus of flavivirus and have similar relationships. Difficulties arise in distinguishing between these two viral infections due to cross-reactivity resulting from similarities in genomic and protein sequences and conformations.
Serum polyclonal antibodies and monoclonal antibody studies isolated from infected subjects indicate that extensive cross-reactivity exists for ZIKV-induced host-produced antibodies against viral membrane protein E. And the antibody aiming at the virus non-structural protein 1 (NS 1) presents a high specificity reaction, so that the possibility of identifying the two virus infections is provided. Balmaseda et al (2017) established a competition ELISA based on NS1 with isolation from ZIKV infectors that binds only ZIKV NS1 monoclonal antibody for diagnosis of ZIKV infection and to distinguish other flaviviruses such as dengue 4 serotypes, West Nile virus and yellow fever virus.
At present, no effective vaccine exists for ZIKV, and an early diagnosis and effective treatment method is further lacked. The NS1 protein plays an important role in the flavivirus life cycle, including viral replication, immune escape, and in pathogenic mechanisms. It has been established that NS1 plays an important role in dengue pathogenesis, related to the severity of the disease. Therefore, the fully human monoclonal antibody aiming at the Zika virus NS1 protein can be a strategy for treating the Zika virus disease.
The preparation technology of the monoclonal antibody is subjected to the hybridoma technology of a mouse antibody, the mouse-human chimeric antibody, the mouse antibody humanized technology and the subsequent human monoclonal antibody preparation technology. The main technologies currently available for large-scale screening of specific antibodies are phage display technology and single B cell antibody technology. Phage display technology can be used to screen for antibodies isolated against any target antigen. However, specific antibodies selected from the heavy and light chain repertoires of randomly combined antibodies whose heavy and light chain pairing is not native to the naturally occurring antibody affect the affinity and function of the antibody. The single B cell antibody technique directly amplifies the variable region genes of the heavy and light chains of an antibody from a single B cell, constructs an antibody expression plasmid, and then expresses the antibody in a cell culture system. This technique allows the isolation of functional antibodies that are predominantly conformation-specific in the infected individual.
Chinese patent application CN107188935A discloses a Zika virus NS1 antigen mutant and application thereof, the antigen mutant is obtained by carrying out gene knockout mutation on a fragment with high homology, and then carrying out gene synthesis, vector construction, prokaryotic expression, antigen purification and immunological functional analysis and screening, and has the effect of reducing the detection rate of dengue positive samples. However, this antigen mutant has a low mutation rate, and the crossover between antibody detection of Zika virus and dengue virus is reduced, and thus cannot be eradicated.
In conclusion, the prior art has the defects of low specificity, incapability of thoroughly distinguishing Zika virus and dengue virus, complicated screening process and the like.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a monoclonal antibody ZKns3G2 and application thereof. The monoclonal antibody ZKns3G2 provided by the invention has high affinity and can be used for distinguishing Zika virus infection and dengue virus infection.
At present, no effective vaccine exists for the new infectious disease Zika virus disease, and an early diagnosis and effective treatment method are further lacked. The invention screens and obtains variable region genes of heavy chains and light chains of antibodies by culturing a limited number of memory B cells, constructs an antibody expression vector, and then expresses the antibodies in a cell culture system. The method is suitable for constructing the fully human monoclonal antibody.
In order to achieve the above object, the present invention provides a monoclonal antibody ZKns3G2, comprising a heavy chain and a light chain, wherein the amino acid sequence information of the variable region of the heavy chain is shown in SEQ ID No. 1; the amino acid sequence information of the variable region of the light chain is shown in SEQ ID NO. 2;
EVQLLESGGGLIQPGGSLRLSCAASGLTVSNNYMNWVRQAPGKGLEWVSIIYSSGSTYYADSVKGRFTISRDTRKNTLYLQMHSLRVEDTAVYYCARYRGWL（SEQ ID NO.1）；
VIWMTQSPSSLSASVGDRVTITCRASQSVSSHLNWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGGDSGTDFTLTIASLQPEDFATYYCQQTYTIPRTFGQGTKVEIK（SEQ ID NO.2）。
the present invention also provides a polynucleotide sequence encoding the amino acid sequence of the variable region of the heavy chain or the variable region of the light chain; the polynucleotide sequence for coding the heavy chain variable region is shown as SEQ ID NO.3, and the polynucleotide sequence for coding the light chain variable region is shown as SEQ ID NO. 4;
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGCTCACCGTCAGTAACAACTACATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGGCTGGAGTGGGTCTCAATTATTTATAGTAGTGGTAGCACGTACTACGCAGACTCCGTGAAGGGCCGCTTCACCATCTCCAGAGACACTCGCAAGAACACTCTGTATCTTCAAATGCACAGCCTGAGAGTCGAGGACACGGCCGTATATTACTGTGCGAGATACCGCGGCTGGCTTGACTACTGGGGCCAGGGAACCCTGGTCACTGTCTCCTCAG（SEQ ID NO.3）；
GTCATCTGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCAAGTCAGAGCGTTAGCAGCCATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATGCTGTGTCCAGTTTACAAAGTGGGGTCCCATCAAGGTTCAGTGGCGGTGATTCTGGCACAGATTTCACTCTCACCATCGCCAGTTTGCAACCTGAAGACTTTGCAACTTACTACTGTCAACAGACTTACACTATCCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC（SEQ ID NO.4）。
the preparation method of the monoclonal antibody ZKns3G2 comprises the following steps:
s1, screening mononuclear cells of peripheral blood of an infected person by using a fluorescent antibody to obtain memory B cells;
s2, culturing the memory B cells obtained in the step S1, adding cytokines to carry out EBV (Epstein-Barr virus) transformation, and screening the existence of the antibodies in the culture supernatant of the B cells by adopting capture ELISA (enzyme-Linked immuno sorbent assay) to obtain B cells containing positive antibodies;
s3, extracting the RNA of the B cell obtained in the step S2, carrying out reverse transcription to form cDNA, amplifying heavy chain and light chain variable regions of the antibody through PCR, and cloning the heavy chain and light chain variable regions to an antibody expression vector to obtain an expression vector containing a monoclonal antibody ZKns3G 2; the PCR primers and PCR amplification procedures are described in the literature (J immunological methods, 2008 Jan 1;329(1-2): 112-24.);
s4, transfecting the expression vector containing the monoclonal antibody ZKns3G2 obtained in the step S3 to 293T cells, and collecting supernatant after 5-6 days.
Preferably, the fluorescent antibodies in step S1 include IgD-FITC, CD19-ECD, CD27-PC7, CD38-APC A750, IgM-PB and CD 45-KO.
Preferably, the cell growth factors in step S2 include CpG, IL21, IL2 and radioactively irradiated cells of peripheral blood mononuclear of healthy human (PBMC).
The invention also provides application of the monoclonal antibody ZKns3G2 in preparation of clinical diagnosis or treatment of Zika virus disease.
Compared with the prior art, the monoclonal antibody ZKns3G2 provided by the invention has the following advantages:
(1) the monoclonal antibody ZKns3G2 provided by the invention is a fully human monoclonal antibody ZKns3G2 which is obtained by B cell culture and antibody cloning technology and targets the Zika virus NS1 protein;
(2) the heavy chain and the light chain of the monoclonal antibody ZKns3G2 provided by the invention are naturally paired, so that the affinity of the antibody is high;
(3) the monoclonal antibody ZKns3G2 provided by the invention has higher Zika virus specificity, and can separate Zika virus from dengue virus;
(4) the monoclonal antibody ZKns3G2 provided by the invention is a functional antibody capable of separating conformational domains which exist in vivo and are difficult to imitate in vitro.
Drawings
FIG. 1 is a schematic structural diagram of a heavy chain expression vector for monoclonal antibody ZKns3G 2;
FIG. 2 is a schematic structural diagram of the light chain expression vector for monoclonal antibody ZKns3G 2;
FIG. 3 is a graph showing the results of the binding reaction of monoclonal antibody ZKns3G2 with viral NS1 protein;
FIG. 4 is a graph of the results of affinity assays for ZKns3G 2;
FIG. 5 is a graph showing the results of detection of the recombinant virus NS1 protein by using a colloidal gold test strip prepared from ZKns3G 2.
Detailed Description
The present invention is further explained with reference to the following specific examples, but it should be noted that the following examples are only illustrative of the present invention and should not be construed as limiting the present invention, and all technical solutions similar or equivalent to the present invention are within the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are commercially available products.
Fluorescent antibodies, antibody expression vectors and flow cytometers are available from Beckman Coulter, Inc (Beckman Coulter, Inc.); a cDNA Synthesis kit (SuperScript III First Strand Synthesis System, invitrogen, #18080051) is available from Shanghai Yubo Biotech, Inc.; antibody expression vectors are described in the literature (J immunological methods. 2008 Jan 1;329(1-2): 112-24).
EXAMPLE 1 preparation of monoclonal antibody ZKns3G2
1. Identification and sorting of memory B cells
1.1 peripheral blood mononuclear cell separation: collecting peripheral vein EDTA anticoagulation of Zika infected patients in recovery period, separating peripheral blood mononuclear cells by using a density gradient centrifugation method, subpackaging the mononuclear cells into 5 multiplied by 106/tube, and placing the tube in liquid nitrogen for freezing;
1.2 fluorescent-labeled antibody staining: dissolving peripheral blood mononuclear cells in a water bath at 37 ℃, washing the peripheral blood mononuclear cells for 3 times by using PBS (phosphate buffer solution), adding an antibody for dyeing, incubating the peripheral blood mononuclear cells for 15min in a dark place at room temperature, washing the peripheral blood mononuclear cells by using the PBS, adding 400 mu L of PBS to suspend a cell up-flow instrument, wherein the flow instrument is a Beckmann Coulter MoFlo Astrios EQ super-high-speed flow cell sorting system;
setting 9 analysis tubes, adding corresponding single fluorescent labeled antibody into the tubes 1 to 7 in the table, adding 7 mixed fluorescent labeled antibodies into the tube 9, and dyeing the sample tube as the tube 9 with a blank tube with cells only;
1.3 sorting of memory B cells: the samples were analyzed on the machine, and live CD45 positive leukocytes were gated out based on 7-AAD and CD 45. B cells were circled according to CD 19. The IgD-IgM-CD27+ CD38low population is defined as memory B cells in the IgM and IgD double-negative B cell population. Memory B cells were sorted into 96-well cell culture plates containing cell culture medium, 25-50 cells per well.
TABLE 11-7 classes of fluorescently labeled antibodies added to the tubes
Pipe number Dyeing pipe arrangement Antibodies and fluorescence of labels Volume (mu L) Fluorescent channel
1 Single dyeing IgD-FITC 10 FL1
2 Single dyeing CD19-ECD 5 FL3
3 Single dyeing 7-AAD 10 FL4
4 Single dyeing CD27-PC7 5 FL5
5 Single dyeing CD38-APC A750 2 FL8
6 Single dyeing IgM-PB 5 FL9
7 Single dyeing CD45-KO 5 FL10
8 Blank tube Without addition of antibody
9 Sample tube Mixture of 7 kinds of antibodies
2. And (4) culturing memory B cells and screening culture supernatant antibodies.
CpG, IL21, IL2, radiation irradiated healthy human PBMC and EBV-containing B95.8 cell culture supernatant were added to 96-well cell culture plates containing memory B cells and cultured for 7-10 days. B cell culture supernatants were screened for the presence of antibodies to zika virus NS1 protein by capture ELISA.
3. Cloning of antibodies
3.1cDNA Synthesis: for B cells in which antibodies against Zika virus NS1 protein were present in the selected supernatant, RNA was extracted and then reverse-transcribed into cDNA. cDNA Synthesis was performed using a kit (SuperScript III First Strand Synthesis System, Invitrogen, # 18080051).
3.2 nested PCR amplification of the heavy and light chain variable region genes of the antibody: PCR primer sequence reference (J Immunol methods. 2008 Jan 1;329(1-2): 112-24.), reaction using Phusion ultra-Fidelity DNA polymerase (Phusion High-Fidelity PCR Master Mix with GC Buffer, NEB, # M0532 s).
3.3 the heavy and light chain variable region PCR products of the antibody were cloned by restriction enzymes (VH, AgeI/SalI, VK, AgeI/Xhol, VL, AgeI/BsiWI) into an antibody expression vector containing the constant region of human IgG1, the heavy chain expression vector is shown in FIG. 1, and the antibody expression vector containing the constant region of human IgG1 is shown in FIG. 2. The measured gene sequences of the heavy chain and light chain variable regions are analyzed by IMGT/V-Quest.
Example 2 analysis of the specificity of the antibodies
1. Production of antibodies: co-transfecting heavy chain and light chain vectors of the constructed antibody with determined sequences into 293T cells, and harvesting culture supernatant containing the antibody after 5-6 days;
2. purifying the antibody, purifying the culture supernatant containing the antibody by a protein A affinity column, and determining the protein content;
3. reaction of the antibody: the antibody is combined with NS1 protein of Zika virus (ZIKA) and dengue virus 1-4 (DENV 1, DENV2, DENV3 and DENV 4), and the ELISA method for capturing NS1 antigen is adopted, and the reaction result is shown in figure 3;
4. antibody affinity assay (BLI): selecting an Anti-Human IgG Fc (AHC) sensor by using an Octet RED384 system of Fortebio company, and obtaining an affinity detection result shown in figure 4, wherein an antibody is used as Ligand and is firstly solidified on the sensor (the concentration is 20 mu g/mL); the antigen was used as an analyte, the binding and dissociation ability of the antibody to the antigen was measured, and the results of the detection of the recombinant viral NS1 protein are shown in fig. 5.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Sequence listing
<110> eighth national hospital in Guangzhou City
<120> monoclonal antibody ZKns3G2 and application thereof
<130> 2018.11.29
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 102
<212> PRT
<213> Zika virus antibody heavy chain amino acid sequence (Zika virus anti-weight chain amino acid sequence)
<400> 1
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Asn Asn
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ile Ile Tyr Ser Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Thr Arg Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met His Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Tyr Arg Gly Trp Leu
100
<210> 2
<211> 107
<212> PRT
<213> Zika virus antibody light chain amino acid sequence (Zika virus anti-weight chain amino acid sequence)
<400> 2
Val Ile Trp Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Ser His
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Val Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Gly Asp Ser Gly Thr Asp Phe Thr Leu Thr Ile Ala Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Thr Ile Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 3
<211> 346
<212> DNA
<213> Polynucleotide sequence encoding amino acids of the antibody heavy chain of Zika virus (Polynucleotide sequences encoding Zika virus anti-weight chain amino acids)
<400> 3
gaggtgcagc tgttggagtc tgggggaggc ttgatccagc ctggggggtc cctgagactc 60
tcctgtgcag cctctgggct caccgtcagt aacaactaca tgaactgggt ccgccaggct 120
ccaggaaagg ggctggagtg ggtctcaatt atttatagta gtggtagcac gtactacgca 180
gactccgtga agggccgctt caccatctcc agagacactc gcaagaacac tctgtatctt 240
caaatgcaca gcctgagagt cgaggacacg gccgtatatt actgtgcgag ataccgcggc 300
tggcttgact actggggcca gggaaccctg gtcactgtct cctcag 346
<210> 4
<211> 322
<212> DNA
<213> Polynucleotide sequence encoding amino acids of the light chain of Zika virus antibody (Polynucleotide sequences encoding Zika virus anti-weight chain amino acids)
<400> 4
gtcatctgga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgtc gggcaagtca gagcgttagc agccatttaa attggtatca gcagaaacca 120
gggaaagccc ctaaactcct gatctatgct gtgtccagtt tacaaagtgg ggtcccatca 180
aggttcagtg gcggtgattc tggcacagat ttcactctca ccatcgccag tttgcaacct 240
gaagactttg caacttacta ctgtcaacag acttacacta tccctcggac gttcggccaa 300
gggaccaagg tggaaatcaa ac 322

Claims (4)

1. A monoclonal antibody ZKns3G2 directed against Zika virus NS1 protein comprising a heavy chain and a light chain, wherein the amino acid sequence of the variable region of the heavy chain is SEQ ID No. 1; the amino acid sequence of the variable region of the light chain is SEQ ID NO. 2.
2. A polynucleotide sequence encoding the monoclonal antibody ZKns3G2 of claim 1, wherein the polynucleotide sequence encodes the amino acid sequence of the variable region of the heavy chain or the variable region of the light chain.
3. The polynucleotide sequence of claim 2, wherein the polynucleotide sequence encoding the variable region of the heavy chain is set forth in SEQ ID No.3 and the polynucleotide sequence encoding the variable region of the light chain is set forth in SEQ ID No. 4.
4. The use of the monoclonal antibody ZKns3G2 of claim 1 in the preparation of a medicament for the diagnosis or treatment of zika virus disease.
CN201811519058.1A 2018-12-12 2018-12-12 Monoclonal antibody ZKns3G2 and application thereof Active CN109535249B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811519058.1A CN109535249B (en) 2018-12-12 2018-12-12 Monoclonal antibody ZKns3G2 and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811519058.1A CN109535249B (en) 2018-12-12 2018-12-12 Monoclonal antibody ZKns3G2 and application thereof

Publications (2)

Publication Number Publication Date
CN109535249A CN109535249A (en) 2019-03-29
CN109535249B true CN109535249B (en) 2021-06-01

Family

ID=65855118

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811519058.1A Active CN109535249B (en) 2018-12-12 2018-12-12 Monoclonal antibody ZKns3G2 and application thereof

Country Status (1)

Country Link
CN (1) CN109535249B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113122659A (en) * 2021-04-27 2021-07-16 北京瀚梅生物科技有限公司 Kit for detecting virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279409A (en) * 2016-08-10 2017-01-04 中国科学院微生物研究所 A kind of zika virus human monoclonal antibody and application thereof
CN106456732A (en) * 2014-04-15 2017-02-22 索伦托治疗有限公司 Antigen binding proteins that bind WISP1
CN106478815A (en) * 2016-10-19 2017-03-08 广州市第八人民医院 Quickly prepare the zika virus specifically method of full human monoclonal antibody and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058944A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456732A (en) * 2014-04-15 2017-02-22 索伦托治疗有限公司 Antigen binding proteins that bind WISP1
CN106279409A (en) * 2016-08-10 2017-01-04 中国科学院微生物研究所 A kind of zika virus human monoclonal antibody and application thereof
CN106478815A (en) * 2016-10-19 2017-03-08 广州市第八人民医院 Quickly prepare the zika virus specifically method of full human monoclonal antibody and application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Delayed and highly specific antibody response to nonstructural protein 1 (NS1) revealed during natural human ZIKV infection by NS1-based capture ELISA";Xiujie Gao 等;《BMC Infect Dis》;20180614;第18卷(第1期);第1-7页 *
"High specificity of human antibody response to nonstructural protein NS1 elicited by Zika virus infection";Xiujie Gao 等;《J Immunol》;20170501;第198卷(第1期);摘要 *
"immunoglobulin heavy chain variable region, partial [Homo sapiens]";Jimenez Gomez,G.等;《Genbank》;20160724;ACCESSION No.ACS95954 *
"寨卡病毒感染宿主NS1抗体反应特征及单克隆抗体在早期诊断中的应用";高秀洁;《中国博士学位论文全文数据库(电子期刊) 医药卫生科技辑》;20190515(第05期);E060-30 *

Also Published As

Publication number Publication date
CN109535249A (en) 2019-03-29

Similar Documents

Publication Publication Date Title
EA019505B1 (en) Methods for obtaining immortalized antibody secreting cells, population of immortalized cells and use thereof
CN110551213B (en) Anti-filovirus monoclonal neutralizing antibody and preparation method and application thereof
JP6055763B2 (en) High affinity human antibody against human cytomegalovirus (CMV) gB protein
CN109232734B (en) Monoclonal antibody specifically binding canine adenovirus, pharmaceutical composition, kit and application thereof
CN115124617B (en) High-affinity anti-hepatitis C virus fully-humanized monoclonal antibody and application thereof
CN114685652B (en) Fully human broad spectrum cross neutralizing antibodies against SARS-CoV-2 and SARS-CoV and uses thereof
CN110272488B (en) Cat calicivirus monoclonal antibody and application thereof
CN114920835A (en) High-affinity fully human monoclonal antibody for resisting rabies virus and application thereof
CN112661841B (en) Fully human monoclonal antibody 17-2 for neutralizing neoepitope of new coronavirus and application thereof
CN109535249B (en) Monoclonal antibody ZKns3G2 and application thereof
CN109553680B (en) Monoclonal antibody ZKns4B8 and application thereof
CN109503712B (en) Monoclonal antibody ZKns2E11 and application thereof
Voigt et al. Therapeutic antibody discovery in infectious diseases using single-cell analysis
CN110655572B (en) Monoclonal antibody for resisting filovirus GP protein and application thereof
CN114316040A (en) Fully human monoclonal antibody for resisting novel coronavirus and application thereof
CN110272497A (en) A kind of anti-cyclic citrullinated peptide tetravalence small molecular antibody of high-affinity and the preparation method and application thereof
TW202041862A (en) Antibody and antibody fragments, kit and method for detecting miltenberger blood group antigen
WO2023102692A1 (en) Human antibodies and antibody combinations for synergistic neutralization of sars-cov-2, and use thereof
CN108794625A (en) A kind of monoclonal antibody of anti-EV-D68 viruses and its preparation and application
CN114957455B (en) Novel coronavirus monoclonal antibody and application thereof
CN116102643B (en) Monoclonal antibody for monkey poxvirus A35 protein and application thereof
CN114133451B (en) Nanometer antibody for toxoplasma virulence factor ROP18 and coding sequence and application thereof
CN116514962A (en) Antibodies or functional fragments thereof that specifically bind to N protein and uses thereof
Kavitha et al. Plurality of diagnostic and prophylactic antibodies to rabies virus-A boon...!
Zhai et al. Monoclonal Antibody Development Technology for Important Human Diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant